Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q1 2026 · 10-Q
Revenue$6.39M$6.39M−92.8% vs Q1 2025 Net Income-$90.05M-$90.05MN/M vs Q1 2025 EPS Diluted-$1.72-$1.72N/M vs Q1 2025 Operating Income-$83,362,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Free Cash Flowderived-$77,421,000N/M Margins · derivedOperating margin-1304.0%−1317.6 pt vs Q1 2025
Net margin-1408.6%−1415.4 pt vs Q1 2025
ended Mar 31, 2026 · filed May 14, 2026 · 44 d after period end